Sandrine Aspeslagh

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease

François‐Xavier Danlos, Anne-Laure Voisin, Valérie Dyevre et al. · European Journal of Cancer · 2018 · 311 citations

Life Sciences, Immunology, Oncology +16

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)

Frédéric Bigot, Eduardo Castañón, Capucine Baldini et al. · European Journal of Cancer · 2017 · 225 citations

Life Sciences, Immunology, Oncology +12

Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma

C. Owen, Xue Bai, Serigne Lo et al. · Annals of Oncology · 2021 · 184 citations · Full text

Medicine, Immunology, Oncology +14

Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation

Marie-Léa Gauci, Émilie Lanoy, Stéphane Champiat et al. · Clinical Cancer Research · 2018 · 143 citations

Medicine, Oncology, Pharmacotherapy +15

Pharmacological sensitivity of ATP release triggered by photoliberation of inositol‐1,4,5‐trisphosphate and zero extracellular calcium in brain endothelial cells

Katleen Braet, Sandrine Aspeslagh, Wouter Vandamme et al. · Journal of Cellular Physiology · 2003 · 116 citations

Life Sciences, Cell Biology, Molecular Biology +17